John L. LaMattina

Devalued and Distrusted

Can the Pharmaceutical Industry Restore Its Broken Image?

• Broschiertes Buch

Produktbeschreibung

While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals.

---

An expert's view on solving the challenges confronting today's pharmaceutical industry

Author John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R&D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, Drug Truths: Dispelling the Myths About Pharma R&D, was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being.

As he toured the country discussing Drug Truths, Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities.

Starting with "4 Secrets that Drug Companies Don't Want You to Know," Devalued and Distrusted provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as:
Why pharmaceutical R&D productivity has declined
Where pharmaceutical companies need to invest their resources
What can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases
How the pharmaceutical industry can regain public trust and resuscitate its image

Our understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading Devalued and Distrusted, you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges.

Get to know the author: Read an interview with John LaMattina or watch a video on ChemistryViews!

Interview: John LaMattina: 30 Years in Pharma

Video: Can the Pharmaceutical Industry Restory its Broken Image?

Produktdetails

• Verlag: Wiley & Sons
• Artikelnr. des Verlages: 1W118487470
• 1. Auflage
• Seitenzahl: 136
• Erscheinungstermin: 9. Januar 2013
• Englisch
• Abmessung: 233mm x 151mm x 15mm
• Gewicht: 1576g
• ISBN-13: 9781118487471
• ISBN-10: 1118487478
• Artikelnr.: 36627992

Autorenporträt

JOHN L. LaMATTINA, PHD, retired as president of Pfizer's Global Research and Development in 2007, where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous honors and awards, including an Honorary Doctor of Science from the University of New Hampshire. Currently a Senior Partner with PureTech Ventures, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (Wiley).

Inhaltsangabe

ACKNOWLEDGMENTS ix INTRODUCTION 1 CHAPTER 1 THE FOUR SECRETS THE DRUG
COMPANIES DON'T WANT YOU TO KNOW 4 Drug Companies Underestimate Dangerous
Side Effects 5 Drug Companies Control Much of the Information Your Doctor
Gets 10 You're Often Prescribed Drugs That You Don't Need 14 Drugs Target
the Symptoms, Not the Cause 19 Conclusion 22 References 23 CHAPTER 2 WHAT
HAS HAPPENED TO R&D PRODUCTIVITY? 25 Impact of Mergers on R&D Productivity
26 Heightened FDA Requirements for NDAs 34 Higher Hurdles Set by Payers 41
Conclusion 46 References 48 CHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING
HEALTH 49 Cancer 51 Diseases of the Brain 54 Cardiovascular Disease (CVD)
60 Diabetes 63 Bacterial Infections 65 Conclusion 68 References 69 CHAPTER
4 IMPROVING R&D OUTPUT 71 The Views of Others 72 Pharma's Blockbuster
Mentality Needs to Change 72 Can "Predictive Innovation" Lead to Greater
Success Rates? 76 Would Royalties Make Scientists More Productive? 78 Will
Drug Repositioning Help Fill the R&D Pipeline? 80 Consultants Don't Always
Have the Facts 82 Personal Views 84 Discovery Must Focus on Productivity 85
Does Size Help or Hinder R&D Productivity? 87 To Outsource or Not to
Outsource? That's the Pharma R&D Question 89 Big Pharma Early Research
Collaborations 92 Conclusion 93 References 95 CHAPTER 5 RESTORING PHARMA'S
IMAGE 96 Illegal Detailing of Drugs 97 Pharmaceutical Companies Should Drop
TV Ads 98 The Need for Greater Transparency 100 How Committed Is Big Pharma
to Rare Diseases? 102 Pharmaceutical Companies and Philanthropy 104 Pharma
Needs to Have Its Scientists Tell Their Stories 105 Conclusion 106
References 107 CHAPTER 6 FINAL THOUGHTS 109 References 114 INDEX 115

Rezensionen

"Oz should invite LaMattina back on his show. Since LaMattina treats all concerns respectfully, Oz needn't worry about feeling devalued or distrusted." (Barron's, 5 May 2014)

"This is an honest book by an insider who believes in the basic good that the industry does." (The Quarterly Review of Biology, 1 September 2013)

"Summing Up: Recommended. General audiences." (Choice, 1 September 2013)

"For those more loosely associated or aspiring to work with in it, I particularly recommend this book as a balanced and informative read on the pressures the industry faces. It should also provide the basis for more reasoned argument and forewarn anyone else potentially ambushed by a TV show." (ChemMedChem, 19 July 2013)

"That said, the suggestions made by LaMattina for improvements in productivity and transparency are timely, and the book makes interesting if unexciting reading." (Chemistry & Industry, 1 June 2013)

"John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the "Dr. Oz" show." (In The Pipeline, 1 December 2012)